Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Biomarkers Identified for Acute Kidney Injury Risk

By Labmedica International staff writers
Posted on 28 Feb 2013
Two biomarkers have been discovered for the early assessment of acute kidney injury (AKI) that can be easily measured in urine.

The two novel biomarkers can detect affected patients roughly 12 to 36 hours earlier than current tests for adult patients and have been subsequently validated using a clinical assay and compared to existing markers of AKI.

Scientists at the Mayo Clinic (Rochester, MN, USA) led a multicenter study to evaluate nearly 340 biomarkers to find the two with the highest correlation to kidney injury risk. In the discovery phase, they enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the validation study, they enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment. The final analysis cohort was a heterogeneous sample of 728 critically ill patients.

Paired urine and blood samples were collected at enrollment and up to 18 hours later by standard methods and centrifuged. Biomarkers were measured with single or multiplexed immunoassays using standard enzyme-linked immunosorbent assays (ELISA). The platforms used were the Luminex 200 (Luminex; Austin, TX, USA); the MSD SECTOR Imager 6000 (Meso Scale Discovery; Gaithersburg, MD, USA), or the Astute140 Meter (Astute Medical; San Diego, CA, USA). The two biomarkers with the highest correlation to kidney injury risk were the Insulin Growth Factor Binding Protein-7 (IGFBP-7) and Tissue Inhibitor of Metalloproteinases-2 (TIMP-2).

The investigators also examined the performance of urine TIMP-2 and IGFBP7 compared to various other markers including urine kidney-injury marker-1 (KIM-1) and urine neutrophil gelatinase-associated lipocalin (NGAL) in terms of discrimination between AKI of different severities and various non-AKI conditions including chronic kidney disease. Unlike existing markers, TIMP-2 and IGFBP7 showed clear separation between AKI and non-AKI conditions.

The authors concluded that urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) are new biomarkers for AKI and perform better than existing markers for predicting the development of moderate or severe AKI within12 hours of sample collection. The risk for major adverse kidney events, such as death, dialysis, or persistent renal dysfunction within 30 days, was elevated sharply for [TIMP-2]•[IGFBP7] above 0.3 and doubled when values were greater than 2.0. The study was published on February 6, 2013 in the journal Critical Care.

Related Links:
Mayo Clinic
Luminex
Meso Scale Discovery



KARL HECHT GMBH & CO KG
Dubai Bio Expo-2015
DIASYS DIAGNOSTIC SYSTEMS

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.